Recombinant @entity24920 Attenuates XXXX After @entity1779 .

@entity1545 @entity72120 @entity2657 @entity548 @entity2880 @entity19 @entity24920 @entity777 @entity8024 @entity12798 @entity10873 @entity1779
BACKGROUND AND PURPOSE: Inflammatory responses and blood-brain barrier (BBB) dysfunction play important roles in @entity1545 after @entity1779 ( @entity1779 ). The metalloprotease @entity24920 (a disintegrin and metalloprotease with thrombospondin type I motif, member 13) was shown to limit inflammatory responses through its proteolytic effects on @entity2880 factor. In the present study, we addressed the role of @entity24920 after experimental @entity1779 . METHODS: @entity1779 was induced in @entity19 by intracerebral infusion of autologous blood. The peri-hematomal inflammatory responses, levels of @entity72120 , pericyte coverage on brain capillaries, and BBB permeability were quantified at 24 hours. Functional outcomes, @entity2657 , and @entity548 volume were quantified at day 3. RESULTS: Treatment with recombinant @entity24920 ( @entity12798 ) reduced the levels of chemokines and cytokines, @entity10873 activity, and microglia activation and neutrophil recruitment after @entity1779 . @entity12798 also decreased @entity777 expression in brain endothelial cells stimulated by lipopolysaccharide, whereas recombinant @entity2880 factor reversed this effect. The anti-inflammatory effect of @entity12798 was accompanied by reduced expression of @entity8024 and less activation of matrix metalloproteinase, enhanced pericyte coverage of brain microvessels, and attenuated BBB disruption. Furthermore, neutrophil depletion protected against BBB damage, and @entity12798 treatment had no further beneficial effect. Finally, treatment of @entity19 with @entity12798 reduced @entity2657 and @entity548 volume and improved neurological functions. CONCLUSIONS: Our findings reveal the importance of @entity12798 in regulating pathological inflammation and BBB function and suggest that @entity12798 may provide a new therapeutic strategy for @entity1779 .
